Date: 2017-09-21
Type of
information: Initiation of the trial
phase: 3
Announcement: initiation of the trial
Company: Janssen Research & Development, a J&J company (USA - NJ)
Product: Tremfya® (guselkumab)
Action
mechanism:
- monoclonal antibody. Guselkumab is a human monoclonal antibody that targets interleukin (IL)-23, and is in Phase 3 clinical development as a subcutaneously administered therapy for the treatment of moderate to severe plaque psoriasis.
- This antibody was generated utilizing the HuCAL antibody library technology licensed from MorphoSys.
Disease: psoriatic arthritis
Therapeutic
area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Country:
Trial
details:
Latest
news:
- • On September 21, 2017, MorphoSys announced that its licensee Janssen Research & Development, has initiated two phase 3 clinical trials to evaluate the efficacy and safety of Tremfya® (guselkumab) in the treatment of patients with psoriatic arthritis.
MorphoSys will receive a milestone payment from Janssen in connection with the start of phase 3 development in psoriatic arthritis. Financial details were not disclosed.
Is
general: Yes
